CFM
CYTH

Catalyst Funds Management’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Catalyst Funds Management’s Portfolio CYTH Stock Details CYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-67
Closed -$93 – 1674
2024
Q1 		$93 Buy
+67
New +$111 ﹤0.01% 1085

Other funds holding CYTH

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FFVM
Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Catalyst Funds Management's CYTH Position: Q2 2024 in Review

Catalyst Funds Management sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q2 2024, closing a stake of 67 shares — an estimated $93 sold.

Catalyst Funds Management first reported a position in CYTH in Q1 2024 and held it in 1 quarter. The position peaked at $93 in Q1 2024. 22 funds tracked by Wall St. Rank hold CYTH as of Q2 2024.

  • Catalyst Funds Management reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 67 Cyclo Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $93.
  • Catalyst Funds Management first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Cyclo Therapeutics, Inc. Common Stock position peaked at $93 in Q1 2024.
  • 22 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.